Twelve investors fund Melbourne biotech startups in 2026. From dedicated drug discovery VCs to university spinout funds, here's who backs biotech, what they need, and how to reach them.
Melbourne has one of Australia's strongest biotech research bases. University of Melbourne, Monash, and RMIT generate spinouts in drug discovery, diagnostics, and medical devices.
Biotech fundraising takes longer than other sectors. Investors expect clinical data, IP filings, and regulatory strategy before writing a serious cheque.
The investor pool splits between dedicated biotech VCs and generalist funds. Dedicated VCs have more patience for the timeline. Generalist funds want a faster path to revenue.
This guide covers 12 Melbourne biotech investors, their check sizes, and what they want to see before a meeting.
| Type | Check size | Sector focus | Website | |
|---|---|---|---|---|
| Brandon Capital Partners | Dedicated biotech VC | A$1M-A$20M | Drug discovery, medtech | brandoncapital.com.au |
| OneVentures | Growth VC | A$500K-A$15M | Biotech, healthtech | oneventures.com.au |
| Main Sequence Ventures | Corporate VC (CSIRO) | A$500K-A$10M | Deep tech, biotech | mainsequence.vc |
| Uniseed | University VC | A$250K-A$5M | University spinouts | uniseed.com |
| MRCF | Dedicated medtech VC | A$500K-A$10M | Medtech, biotech | mrcf.com.au |
| Artesian VC | Multi-strategy VC | A$500K-A$10M | Healthtech, biotech | artesianvc.com |
| Yuuwa Capital | Biotech VC | A$500K-A$8M | Drug development | yuuwacapital.com.au |
| Blackbird Ventures | Independent VC | A$200K-A$50M | Biotech, life sciences | blackbird.vc |
| Regal Funds Management | Multi-asset fund | A$1M-A$30M | Listed biotech, growth | regalfm.com |
| MedTech Actuator | Accelerator/VC | A$50K-A$500K | Medtech, early-stage | medtechactuator.com |
| Skalata Ventures | Accelerator/VC | A$200K-A$2M | Early-stage biotech | skalata.co |
| Australian Biotech Association Fund | Industry VC | A$250K-A$5M | Biotech, therapeutics | ausbiotech.org |
Share your biotech pitch securely
Ellty gives you trackable data room links with granular access control for sensitive IP documents.
Start free 14-day trialWhat biotech investors look for
Melbourne biotech investors check IP ownership, clinical pipeline, regulatory pathway, and team credentials. A strong science team without clinical strategy is hard to fund.
Dedicated biotech VCs like Brandon Capital and MRCF have in-house scientific advisors. They run deep technical diligence before term sheets.
Read our sell-side due diligence guide to understand how biotech investors structure technical diligence. Most want preclinical data at minimum.
Revenue timelines for biotech are long. Investors model 5-10 year return horizons and want to see a clear licensing or acquisition exit path.
Melbourne biotech founders often underestimate how much IP diligence investors run before a first term sheet. File your key patents before you open a data room.
12 Melbourne biotech investors
1. Brandon Capital Partners
Australia's only specialist biotech/medtech VC - manages MRCF funds backed by universities and institutes.
Recent Deals: MRCF Fund VI actively deploying 2025-2026; clinical-stage biotech portfolio spanning oncology and immunology
LinkedIn: Brandon Capital Partners LinkedIn
Sector Focus: Biotech, medtech, life sciences
Stage Focus: Seed, Series A, Series B
Location: Melbourne, Australia
Website: brandoncapital.com.au
2. OneVentures
Michelle Deaker's data-led fund - strong track record in health, biotech, and enterprise AI from Melbourne.
Recent Deals: Zepto A$25M Series A (2025) - instant payments; health AI and biotech investments ongoing through Fund IV
LinkedIn: OneVentures LinkedIn
Sector Focus: Health, biotech, AI, enterprise
Stage Focus: Seed, Series A, Series B
Location: Melbourne, Australia
Website: oneventures.com.au
3. Main Sequence Ventures
CSIRO's VC - the only fund bringing direct national research infrastructure alongside the biotech cheque.
Recent Deals: Presagen Series B (2025) - AI for IVF; Nutromics seed - biosensor wearables; health AI portfolio active
LinkedIn: Main Sequence Ventures LinkedIn
Sector Focus: Health AI, biotech, deep tech
Stage Focus: Seed, Series A
Location: Melbourne, Australia
Website: mseq.vc
4. Uniseed
Commercialises IP from Australian universities and CSIRO at earliest stage - pre-revenue is fine here.
Recent Deals: Multiple university spinout investments 2025; biomedical and life science IP commercialisation ongoing
LinkedIn: Uniseed LinkedIn
Sector Focus: University IP, biotech, life sciences
Stage Focus: Pre-seed, seed
Location: Brisbane, Australia
Website: uniseed.com
5. Medical Research Commercialisation Fund
Clinical-stage specialist managed by Brandon Capital - backs ANZ research at the translational gap.
Recent Deals: Biotech and medtech clinical-stage portfolio active 2025-2026; ANZ research commercialisation focus ongoing
LinkedIn: Medical Research Commercialisation Fund LinkedIn
Sector Focus: Clinical biotech, medtech, translational research
Stage Focus: Seed, Series A
Location: Melbourne, Australia
Website: mrcf.com.au
6. Artesian VC
Broadest mandate in this list - health AI to diagnostics to impact biotech, if the team is right.
Recent Deals: 5 investments past 12 months across health AI, diagnostics, and impact-led biotech in ANZ and ASEAN
LinkedIn: Artesian VC LinkedIn
Sector Focus: Health AI, diagnostics, biotech, impact
Stage Focus: Seed, Series A
Location: Melbourne, Australia
Website: artesianinvest.com
Know which investor reviewed your biotech dossier
Ellty tracks every investor interaction with your data room so you follow up at the right time.
Start free 14-day trial7. Yuuwa Capital
WA-based life sciences specialist investing nationally - deep clinical networks in ANZ biotech.
Recent Deals: Life sciences investments 2025 across Western Australia and nationally; clinical-stage biotech focus active
LinkedIn: Yuuwa Capital LinkedIn
Sector Focus: Life sciences, clinical biotech, medtech
Stage Focus: Seed, Series A
Location: Perth, Australia
Website: yuuwa.com.au
8. Blackbird Ventures
Backs biotech founders building global category leaders - needs genuine IP moat and global ambition.
Recent Deals: Wild Futures programme backing health AI founders in Melbourne; biotech in broader portfolio active
LinkedIn: Blackbird Ventures LinkedIn
Sector Focus: Biotech, health AI, consumer health
Stage Focus: Seed to growth
Location: Sydney, Australia
Website: blackbird.vc
9. Regal Funds Management
ASX-listed growth fund with dedicated life sciences portfolio - needs revenue or near-clinical stage.
Recent Deals: Growth-stage ASX-listed biotech positions growing; life sciences fund deploying actively 2025-2026
LinkedIn: Regal Funds Management LinkedIn
Sector Focus: Life sciences, biotech, growth-stage
Stage Focus: Growth, pre-IPO
Location: Sydney, Australia
Website: regalim.com.au
10. MedTech Actuator
Accelerator exclusively for medical technology startups - best pre-revenue entry with clinical mentorship.
Recent Deals: 40+ MedTech cohort companies supported through 2025; medical device and health tech acceleration ongoing
LinkedIn: MedTech Actuator LinkedIn
Sector Focus: Medtech, health innovation, medical devices
Stage Focus: Pre-seed, seed
Location: Melbourne, Australia
Website: medtechactuator.com.au
11. Skalata Ventures
Best general pre-revenue entry point - 6-month accelerator with capital and structured mentorship.
Recent Deals: Paperly A$3M seed (Nov 2025); cohort programs include biotech and healthtech startups 2025-2026
LinkedIn: Skalata Ventures LinkedIn
Sector Focus: Early biotech, healthtech, SaaS
Stage Focus: Pre-seed, seed
Location: Melbourne, Australia
Website: skalata.co
12. AusBiotech
Industry body connecting biotech founders to investors, government programs, and global partnering events.
Recent Deals: 25+ biotech partnering events 2025; BIO conference bringing US and ANZ VCs together for Melbourne founders
LinkedIn: AusBiotech LinkedIn
Sector Focus: Biotech networking, industry connections
Stage Focus: All stages (network)
Location: Melbourne, Australia
Website: ausbiotech.com.au
Clinical trials and investor expectations
Melbourne biotech investors set hard milestones around clinical data. A Phase 1 completion is the minimum most dedicated VCs need before leading a Series A.
Pre-clinical companies can raise from Uniseed, MedTech Actuator, and MRCF. Expect smaller cheques and more intensive board involvement at this stage.
Use virtual data room software to share clinical protocols with different investors under NDAs. Biotech data rooms need strict access controls for unpublished trial data.
TGA regulatory strategy matters as much as clinical data to Australian biotech investors. Have a clear TGA and FDA pathway documented before you open your raise.
How to structure a biotech raise
Start with non-dilutive government grants before approaching equity investors. MTP Connect, MRFF, and BioMedTech Horizons all fund early Melbourne biotech.
Use fundraising tools to track your raise pipeline across government programs and VC simultaneously. Biotech raise timelines are long - you need to run multiple tracks at once.
For M&A exits and later-stage liquidity, review our mergers and acquisitions guide to understand how biotech acquisitions are structured. Most Melbourne biotech exits are acquisition, not IPO.
Engage a biotech-specialist corporate adviser for your Series A and beyond. Biotech deal terms differ significantly from software VC - you need specialised legal and financial advice.
IP strategy for biotech fundraising
Melbourne biotech investors verify IP ownership, freedom to operate, and patent filing timeline first. Unfiled IP is the single fastest way to lose investor interest.
File PCT applications before you open any investor conversations. International filing signals seriousness and protects your disclosure in investor meetings.
Use granular permissions in your data room to share different IP documents with different investors. Show filed patents to all investors but unpublished applications only to those under NDA.
Our AI due diligence guide covers how investors use AI tools to screen IP portfolios. Expect AI-assisted patent landscape analysis from any sophisticated biotech investor.
How to pitch a Melbourne biotech investor
Lead with IP status and clinical pathway. Biotech investors check patent filings before anything else.
- 1.File patents before your first pitchUnfiled IP blocks term sheets. File PCT before you open any investor conversations.
- 2.Map your regulatory pathway clearlyShow TGA and FDA strategy. Investors want a dated milestone plan, not a general narrative.
- 3.Share clinical data under NDA firstSend a data room invite before your first meeting. Investors review data before they allocate time.
- 4.Quantify your market and exit compsName three acquisition comps from the last 5 years. Biotech exits are almost always M&A.
- 5.Follow up with one clinical milestoneA preclinical result, ethics approval, or phase 1 enrollment update. One milestone per follow-up.
How Ellty helps you land a biotech investor in Melbourne
Ellty is a data room for biotech founders. Control IP access, track investor activity, and close faster.
- 1.Organise your biotech documentsAdd patents, clinical protocols, and regulatory docs. Set NDA-gated access per investor group.
- 2.Share trackable linksSend each investor a unique link. Ellty logs every open and time spent per document.
- 3.Follow up at the right momentSee who went deep on your clinical data. Call them the same day they're active in your data room.
Melbourne biotech investors: common questions
- Most dedicated VCs enter at pre-clinical or Phase 1. Uniseed and MedTech Actuator go earlier.
- Dedicated VCs usually want preclinical data. Generalist VCs often want Phase 1 results minimum.
- Seed rounds take 3-6 months. Series A with dedicated VCs takes 6-12 months for full diligence.
- Patents, clinical protocols, preclinical data, regulatory pathway, team CVs, and financials.
- Approach MRCF first. They're earlier stage and MRCF approval often leads to Brandon involvement.
